A 46-year-old with psoriatic arthritis and a BMI of 38 still has active disease on adalimumab (Humira) 40 mg every other week. What do you do? Switch class, optimize methotrexate, or ask whether the dose itself is too low?
All News
We have spent years telling patients with PsA that weight loss may improve symptoms and reduce cardiometabolic risk. A new ACR 2026 abstract asks the more provocative question: could GLP-1–based therapy influence PsA outcomes even after accounting for the change on the scale?
IL-23 therapies are among the most efficacious and safest treatment options for patients with skin psoriasis. The enthusiasm for IL-23 agents for PsA is perhaps more tempered; while efficacy has been demonstrated for peripheral joint disease, there is concern that these agents are not effective in patients with axial disease.
Ab#2804 #ACR26 @RheumNow BE BOLD: Bimekiz v Risankiz in PsA, 24w H2H P3B W16 (primary endpt): ACR50: BKZ 49% v 38% RZB, p=.006, W24: 56% v 44% MDA, ACR50+PASI100 NOT signif PASI100: BKZ earlier, equal later BKZ - better for jts, earlier skin but equal later, more Candida #ACRBest https://t.co/q6g6zQMutY
Kaka et al: In a national PsA analysis, 76.7% met GLP-1 eligibility criteria, yet none reported treatment in the analyzed sample. A striking gap between metabolic risk and care. An important call for action. @rheumnow #ACR2026 #ACRBest Abstract#1343 https://t.co/RP1d8PEBwe
Rex et al: In PsA, rheumatologists estimated GLP-1 use at 14%, while 37% were considered strong candidates. The treatment gap may be one of the biggest stories. Who should take the lead in metabolic care? @rheumnow #ACR2026 #ACRBest Abstract#1315 https://t.co/nTPf2MhKN5
